Edition:
United Kingdom

CTI Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

1.83USD
17 Aug 2018
Change (% chg)

$-0.07 (-3.68%)
Prev Close
$1.90
Open
$1.90
Day's High
$1.90
Day's Low
$1.82
Volume
137,143
Avg. Vol
151,151
52-wk High
$5.36
52-wk Low
$1.82

Chart for

About

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for... (more)

Overall

Beta: 0.62
Market Cap(Mil.): $140.98
Shares Outstanding(Mil.): 42.98
Dividend: --
Yield (%): --

Financials

  CTIC.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.80 -- --
ROI: -85.83 1.78 14.61
ROE: -127.14 3.28 16.33

BRIEF-Cti Biopharma Reports Q1 EPS Loss Per Share Of $0.08

* AS OF MARCH 31, 2018, CASH AND CASH EQUIVALENTS TOTALED $104.6 MILLION, COMPARED TO $43.2 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

03 May 2018

BRIEF-Children's Hospital Of Philadelphia Foundation To Engage In Dialogue With Spark Therapeutics To Be Allowed To Designate At Least 1 Board Member

* CHILDREN'S HOSPITAL OF PHILADELPHIA FOUNDATION - TO ENGAGE IN DIALOGUE WITH SPARK THERAPEUTICS TO BE ALLOWED TO DESIGNATE AT LEAST 1 BOARD MEMBER

09 Mar 2018

BRIEF-CTI Biopharma Q4 Loss Per Share $0.33

* CTI BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

07 Mar 2018

BRIEF-Tempest Therapeutics Inc Says It Has Raised $25.2 Million In Equity Financing

* TEMPEST THERAPEUTICS, INC FILES TO SAY IT HAS RAISED $25.2 MILLION IN EQUITY FINANCING - SEC FILING​

01 Mar 2018

BRIEF-Growth Equity Opportunities Fund Reports 6.0 Pct Stake In CTI Biopharma

* GROWTH EQUITY OPPORTUNITIES FUND V LLC REPORTS 6.0 PERCENT STAKE IN CTI BIOPHARMA CORP AS OF FEB 8 - SEC FILING

20 Feb 2018

Earnings vs. Estimates